Institut Catala d'Oncologia

L'Hospitalet de Llobregat, Barcelona 08908

1 studies enrolling now · 6 studies all time

What they study most

Advanced Cancer, BRAF V600E-mutant Metastatic Colorectal Cancer, Metastatic Castration-Resistant Prostate Cancer, Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL), Renal Cell Carcinoma, Small Cell Lung Cancer

Studies at this site

• A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma — Recruiting now
• Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer — Completed
• A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer — Withdrawn before enrolling
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects — Completed